Eiger BioPharmaceuticals, Inc. (EIGR)
| Market Cap | 44.60M |
| Revenue (ttm) | 13.48M |
| Net Income (ttm) | -96.78M |
| Shares Out | 44.16M |
| EPS (ttm) | -2.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 341,889 |
| Open | 1.00 |
| Previous Close | 0.97 |
| Day's Range | 0.95 - 1.02 |
| 52-Week Range | 0.95 - 9.92 |
| Beta | 1.95 |
| Analysts | Strong Buy |
| Price Target | 9.38 (+828.71%) |
| Earnings Date | May 4, 2023 |
About EIGR
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the tre... [Read more]
Financial Performance
In 2022, EIGR's revenue was $13.48 million, an increase of 11.05% compared to the previous year's $12.14 million. Losses were -$96.78 million, 185.3% more than in 2021.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for EIGR stock is "Strong Buy." The 12-month stock price forecast is $9.38, which is an increase of 828.71% from the latest price.
News
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting Planned by End of Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: On Track to Complete Randomization by End of Q2 Phase 3 HI AVANT ...
10 Companies That Had Tons of Money in SVB When It Collapsed
Since SVB Financial's (NASDAQ: SIVB) principal subsidiary, Silicon Valley Bank, collapsed last week, Wall Street has been in turmoil. With SVB seized by government regulators and New York's Signature...
New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19
- Phase 3 TOGETHER data showed early treatment with a single dose of peginterferon lambda (Lambda) in patients with mild-to-moderate COVID-19 infections resulted in significantly decreased clinical e...
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - January 9, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharma...
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Eiger Investors of a Lead Plaintiff Deadline of January 9, 2023
NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Attention Eiger BioPharmaceuticals, Inc. ("Eiger") (NASDAQ: EIGR) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenc...
EIGR FINAL DEADLINE NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - EIGR
New York, New York--(Newsfile Corp. - January 6, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) b...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 9, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of inves...
Eiger Class Action: Levi & Korsinsky Reminds Eiger BioPharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2023 - EIGR
New York, New York--(Newsfile Corp. - January 6, 2023) - Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securiti...
DEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - January 6, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharma...
EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023
NEW YORK , Jan. 6, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR). ...
MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - January 5, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharma...
EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securities lawsuit. CLASS...
EIGER BIOPHARMACEUTICALS, INC. (NASDAQ: EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)
Did you lose money on investments in Eiger BioPharmaceuticals, Inc.? If so, please visit Eiger BioPharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or ...
EIGER BIOPHARMACEUTICALS, INC. (EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)
Did you lose money on investments in Eiger BioPharmaceuticals, Inc.? If so, please visit Eiger BioPharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or p...
EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors Of a Class Action Lawsuit and Upcoming Deadline
New York, New York--(Newsfile Corp. - January 4, 2023) - Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securiti...
MONDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - January 4, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharma...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eiger BioPharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2023 - (NASDAQ: EIGR)
NEW YORK , Jan. 4, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eiger BioPharmaceuticals, Inc.. Shareholders who purchased shares of EIGR during the class per...
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - EIGR
NEW YORK , Jan. 2, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) between March 10, ...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eiger BioPharmaceuticals, Inc., of Class Action Lawsuit and Upcoming Deadline - EIGR
New York, New York--(Newsfile Corp. - December 30, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), and certain officer...
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - December 30, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPhar...
EIGR Investors Have Opportunity to Lead Eiger BioPharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES , Dec. 29, 2022 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit agai...
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - December 29, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPhar...
EIGER BIOPHARMACEUTICALS, INC. (EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors Of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)
Did you lose money on investments in Eiger BioPharmaceuticals, Inc.? If so, please visit Eiger BioPharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or p...
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - EIGR
New York, New York--(Newsfile Corp. - December 28, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)...